ArticleJournal of cellular and molecular medicine2025
Dihydromikanolide Inhibits ROS-Mediated NLRP3 Inflammation via Antioxidant Nrf2 Activation and Mitophagy Induction in LPS/ATP-Stimulated Macrophages.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Asiatic Acid-Loaded Hydrogel Ameliorates Diabetic Periodontitis via Mitophagy-Mediated M2 Macrophage Polarization.ACS omega · 2026Article
- A new mechanism regulating microglial NLRP3 inflammasome: FMR1 mediates NLRP3 mRNA stability.PloS one · 2026Article
- Dihydromikanolide Inhibits ROS-Mediated NLRP3 Inflammation via Antioxidant Nrf2 Activation and Mitophagy Induction in LPS/ATP-Stimulated Macrophages.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Dihydromikanolide (DHK) is a natural product in Mikania species. We examined the anti-inflammatory molecular mechanisms of DHK employing in vitro RAW264.7 macrophages and in vivo BALB/c mice under LPS/ATP stimulation. We found that DHK suppressed NLRP3 inflammasome, procaspase-1 activation and then pro-inflammatory IL1β expression in LPS/ATP-stimulated RAW264.7 cells. Notably, DHK-triggered autophagy in RAW264.7 cells was demonstrated by increased LC3-II accumulation, p62/SQSTM1 expression, Beclin-1/Bcl-2 ratio and PI3K/AKT/mTOR phosphorylation. Besides, DHK increased Parkin and Pink-1 protein expressions implying mitophagy induction in RAW264.7 cells. Interestingly, DHK enhanced Nrf2 nuclear translocation and provoked antioxidant HO-1, NQO-1 and γ-GCLC expressions in RAW264.7 cells. Nrf2 knockdown reversed DHK-inhibited LPS/ATP-stimulated IL1β expression in RAW264.7 cells. Interestingly, LPS/ATP-stimulated NLRP3 inflammasome and IL1β expression were inhibited by DHK, Mito-TEMPO (a mitochondrial ROS inhibitor), or N-acetylcysteine (a ROS inhibitor). In vivo study revealed that DHK attenuated wet/dry weight ratio of lung tissue, lung neutrophil intrusions and pulmonary oedema, and reduced the increased total cells, neutrophils, TNFα and IL1β expression in bronchoalveolar lavage fluid (BALF) in LPS-stimulated BALB/c mice. DHK alleviated LPS-induced pathological alterations of lung through inhibiting NLRP3 inflammation, enhancing antioxidant Nrf2 pathway and inducing mitophagy in LPS-stimulated BALB/c mice. Dihydromikanolide may be a potential therapeutic agent for inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.